BX005
AXP000219.1 · Phage therapy
- Platform
- phage cocktail (non-engineered)
- Originator
- BiomX
- Sponsor
- BiomX
Names
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Staphylococcus aureus bacteriophage (cocktail)
- Replication
- replicating
- Route
- topical
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05240300 | A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis | Withdrawn | Phase 1/2 | 2022-05 | 2023-06 | 0 | Atopic Dermatitis |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38212021 | [Comprehensive evaluation of Pinellia ternata germplasm resources based on phenotypic trait classification]. | Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica | 2023 | name in abstract: BX005 |
Notes
Topical anti-Staphylococcus aureus phage cocktail for atopic dermatitis. Its registered phase 1b/2a trial NCT05240300 was withdrawn, so the product has a registered trial but no published human use; kept on the registered-trial limb of the scope rule and flagged here.
How to cite
BX005 (AXP000219.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000219.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.